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Xenotropic murine leukemia virus-related virus (XMRV) is a newly identiﬁed gamma retrovirus and may be associated with
prostate cancer- (PC) and chronic fatigue syndrome (CFS). Since its identiﬁcation in 2006 and detection of polytropic murine
lenkemia virus (MLV)-like sequences in CFS patients in 2010, several test methods including nucleic acid testing methods and
serological assays have been developed for detection of XMRV and/or MLV-like sequences. However, these research assays have
not yet been validated and evaluated due to the lack of well-characterized reference materials. Mouse DNA contamination should
be carefully checked when testing human specimens in order to avoid false-positive detection of XMRV or MLV-like sequences.
1.Introduction
When XMRV was ﬁrst identiﬁed in PC patients in 2006 [1],
it did not get much public attention until a science paper
published in 2009 reported its detection in a majority (67%)
of CFS patients and about 4% of healthy Americans [2]. In
this report, XMRV was shown to be infectious and could
be isolated from peripheral mononuclear cells (PBMCs)
and plasma, indicating that it is the ﬁrst gamma retrovirus
that infects humans and may be associated with human
diseases[1,2].Furthermore,ifconﬁrmed,itwasthoughtthat
millions of persons worldwide may harbor the new virus and
thus pose a serious concern to public health and the safety of
blood transfusion and organ transplantation. These ﬁndings
greatly stimulated the interest of scientists in academia and
government agencies to address both public health and
scientiﬁc concerns about the newly identiﬁed retrovirus and
its possible association with human diseases. However, the
studies that followed the original publications have yielded
conﬂicting ﬁndings and generated more controversy than
consensus about XMRV detection and its potential disease
association (see reviews [3–11]). In 2010, Lo et al. reported
the detection of polytropic MLV-like sequences in 87% of
CFSpatients[12].MLV-likesequencesarediﬀerentfrom,but
verysimilarto,XMRV[12].ThedetectionofpolytropicMLV
in CFS patients suggested that XMRV may be only one of
an apparent cluster of MLV-like viruses identiﬁed in patient
specimens. In this paper, we describe and summarize the
various testing methods and assays that have been employed
for detection of XMRV and/or MLV-like virus infection in
the studies that have been published until the present time.
2. XMRV Testing Methods
A variety of test methods have been employed to detect
XMRV in cell culture studies and clinical specimens. Poly-
merase chain reaction (PCR) assay (nested and real-time
PCR), transcription-mediated ampliﬁcation assay (TMA),
and ﬂuorescence in situ hybridization (FISH) have been
used for direct detection of viral sequences. Several serologic
assays for detection of circulating antibodies against XMRV
have been reported, including ﬂow cytometry (FACS), West-
ern blot (WB), chemiluminescence-based immunoassays
and enzyme linked immunosorbent assay (ELISA), and so
forth. Immunohistochemical staining (IHC) has been used
for direct detection of viral proteins, while cell culture assays
were used for isolation and detection of infectious virus.2 Advances in Virology
2.1. Nucleic Acid Testing (NAT). Viral nucleic acid detection
by reverse transcription- (RT-) based PCR or DNA PCR
methods has been widely used for detection of XMRV
and/or MLV-like sequences, but the results have generated
controversial ﬁndings partly because of the diﬀerences in
detectionsensitivityandspeciﬁcity[11,13,14].Severalissues
need to be considered when using PCR to detect XMRV
and/or MLV-like sequences. Mikovits et al. emphasized that
the PCR template is critical for successful ampliﬁcation and
relatively high-detection rate of XMRV [15, 16]. They found
that by using DNA extracted from inactivated PBMCs as
template, only 7% and 21% of CFS patients were positive
in single-round and nested PCR, respectively. By using
viral RNA template from activated PBMC and cocultured
cells and RT PCR, the detection rate was 72% and 89%,
respectively [15, 16]. Using activated PBMC can signiﬁcantly
improvedetectionsensitivitybecauseMLVsandotherclosely
related retroviruses rely on mitosis to access the host cell
chromosomes [17] and the copies of XMRV in activated
cells are increased. Their results suggested that it may be
more sensitive to detect viral RNA rather than proviral DNA,
which was done in their original science paper [2]. The
amount of DNA in the template is also critical. Danielson
et al. found that XMRV was detected in 3.2% of the
patients when 100–140ng of prostate tissue DNA were used,
compared with the positivity of 22.2% when 650ng DNA
were used [18]. However, Lo et al. reported that 87% of
CFS patients were positive for MLV-like viral sequences
when less than 50ng of DNA per reaction and similar
primers from XMRV were used [12]. The selection of PCR
primers is another crucial factor that may aﬀect detection
of XMRV-speciﬁc sequences. The PCR primers previously
claimed to be speciﬁc for XMRV have been found to be able
to readily amplify MLV sequences from a variety of mice
and some human cell lines [19–22], including polytropic
MLV-like sequences identiﬁed by Lo et al. [12]. The typical
24 nucleotide deletion within the gag leader region of the
XMRV genome is also found in some MLV sequences,
endogenous retroviruses and in several mouse strains [19,
22]. In addition, Chow and Ikeda did not detect the 24-
nt deletion in the gag leader region in their studies [14].
These results indicate that it may be diﬃcult to design PCR
primers that are exclusively speciﬁc for XMRV due to the
high-sequence homology between XMRV and MLVs and
even endogenous retroviral sequences. However, Schlaberg
et al. reported a quantitative PCR for speciﬁc detection of
XMRV by using primers from XMRV integrase gene, which
are 100% conserved in 3 published XMRV sequences (VP35,
VP42, and VP62) and share only 80–85% sequence identity
with the most similar murine retroviruses [23]. They could
consistently detect 50 copies of the XMRV proviral clone
and 5 copies at 50% of hit rate [23]. Van Kuppeveld et al.
also observed that both the real time PCR assay and the
nested PCR assay could detect at least 10 copies of XMRV,
indicating similar sensitivity [24]. Some studies found that
XMRV could only be ampliﬁed by gag primers but not env
or pol primers, or vice versa; or that detection sensitivity
relies on primer sequences and locations. Danielson et al.
reported that XMRV gag primers were at least 10-fold less
sensitivethanenv primers;andpol primerstendedtoamplify
a competing region from the human genome. They could
not detect XMRV in patient tissue samples by nested RT-
PCR with primers speciﬁc for gag and pol genes, regardless
of whether 100 or 650ng of DNA was used as template [18].
Stoye et al. reported that the XMRV env primers yielded
the most positive results [14]. However, Lo et al. found
gag primers were more sensitive than env primers when
detecting MLV-like sequences [12]. Oakes et al. found that
53% (19/36) of the healthy volunteers and 1.8% (2/112) of
the CFS patients yielded PCR products when using XMRV
gag primers, but no positive ampliﬁcation was observed
when using qPCR with pol primers [20]. Switzer et al.
[36] tested 162 PC patients and found that PCR products
were obtained for gag, pol, and env from one patient, from
pol and env from a second, and pol alone from a third
case. Furthermore, PCR was not successful in all replicates
on individual samples, indicating that multiple primer sets
and repeats may be necessary for accurate detection of
XMRV, possibly due to the very low viral titers in clinical
samples [14]. The real reasons are not clear due to lack
of consensus results. Although XMRV sequences appear
to be highly conserved, variations have been consistently
mentioned and may account for some of the negative results
[5, 15, 25].
A major concern in regard to XMRV detection by PCR
is false-positive results caused by contamination. Recently,
four publications that appeared in the journal Retrovirology
identiﬁed three potential sources of contamination in PCR-
based studies of XMRV. Robinson and Oakes et al. reported
independently that all XMRV-positive samples in their
analysis were also positive for mouse DNA when assayed
using a mouse mitochondrial DNA PCR or intracisternal A
particle (IAP) assay [19, 20]. Hue et al. conﬁrmed that 2.2%
(5/411) of human cell lines screened were positive for MLVs
[22]. Sato et al. found that commercial RT-PCR reagents
were contaminated with MLV RNA [21]. The contamination
was thought to originate from the hybridoma cell line from
which the monoclonal antibody used in the polymerase
reaction mixture to facilitate hot-start PCR was prepared.
These results indicate that mouse DNA contamination is
widespread and can confound XMRV detection in human
samples. Furthermore, Hue et al. compared the published
XMRV sequences with those from XMRV positive 22Rv1
cell, and found the genetic distance among 22Rv1-derived
sequences exceeds that of XMRV sequences from patients,
indicating that XMRV detected in patients may result
from laboratory contamination rather than a true human
infection [22]. Interestingly, 22Rv1 cell line was derived
from a human prostate cancer xenograft (CWR22) that
was serially passaged in nude mice in 1990s. Paprotka et
al. recently reported that XMRV was the recombinant of
two endogenous MLVs during passage of the CWR22 PC
xenograft [26],suggestingthatXMRVisalaboratory-derived
virus and may have contaminated samples for more than a
decade, but it may not infect people. These results clearly
show that extraprecautions must be taken to avoid mouse
DNA contamination and false-positive ampliﬁcation from
human cell lines that harbor xenotropic MLVs since they areAdvances in Virology 3
closely related to XMRV. PCR methods have been used to
detect mouse mitochondrial DNA [12], cox2 DNA [20], and
IAP [19, 20]. IAPs are endogenous transportable elements
present at the level of about 1000 copies per mouse genome
[27]. Robinson et al. found the mtDNA PCR was 100-fold
less sensitive than that for IAP when testing in both McCoy
cell and RAW 264.7 cell DNA [19], suggesting that IAP PCR
may be more suitable for ﬁnding contamination of murine
sequences.
Due to concerns about variations in nucleic acid-based
methods that have been used to study XMRV, the National
Heart, Lung, and Blood Institute (NHLBI) under the leader-
ship of the Health and Human Services (HHS) sponsored an
XMRV Blood Scientiﬁc Working Group (BSWG) to validate
the testing assays that have been developed and used in
diﬀerent laboratories for CFS and blood donor testing [28].
Preliminaryresultsofthisworkinggroupindicatedthatmost
nucleic acid testing assays used in diﬀerent labs were able to
achieve similar levels of sensitivity and speciﬁcity based on
the spiked XMRV panels [28]. However, when testing CFS
samples, no consensus of results was observed. Therefore, it
is still not clear if assay methodology alone could account for
the large diﬀerences observed when testing clinical samples.
2.2. Serology. Antibody detection is considered as strong
evidence of XMRV infection, in particular, in the absence of
positive PCR results, or when the PCR results are not very
reliable due to diﬀerences in assay sensitivity and speciﬁcity.
High-throughput serologic assays that detect XMRV-speciﬁc
antibodies would be of great value for determining the
epidemiologyofpossibleXMRVinfectionandforaddressing
the association of XMRV infection and human diseases if
they exist at all. However, the nature and kinetics of the
antibody response to XMRV infection have not been well-
characterized; or it may be premature to discuss the antibody
responses since XMRV infection of humans has yet to be
proven.
Lombardi et al. ﬁrst reported on speciﬁc immune
responses to XMRV in CFS patients [2]. They used FACS
to measure the antibody against XMRV by mixing patient
plasma with a mouse B cell line expressing recombinant
spleen focus-forming virus (SFFV) env protein. Because
XMRV shares >90% overall nucleotide sequence identity
with known MLVs, cross-reactivity between anti-MLV anti-
bodies and XMRV proteins has been observed and 50%
(9/18) of CFS patients were shown to be reactive [2].
Furthermore,anti-XMRV-positiveplasmasamplesfromCFS
patients blocked the binding of anti-SFFV env antibody to
SFFV env on the cell surface. They claimed that FACS was
one of the most sensitive blood-based assays for detection of
anti-XMRV env antibody in patient plasma and could detect
82% (47/57) of XMRV infection in CFS patients [15, 16].
Arnold et al. developed a single-round reporter gene based
on neutralizing antibody assay and found that 27.5% (11/40)
PC patients were anti-XMRV antibody positive [29]. In their
system, anti-XMRV antibody was conﬁrmed by blocking the
bindingandinfectionofXMRV-HIVpseudovirusexpressing
XMRV env protein with the reporter cell line JC53BL-
13 that carries the ﬁreﬂy luciferase and β-galactosidase
under the control of the HIV-1 LTR. The results were
in complete concordance with both PCR and FISH for 7
patients in whom 3 assays were conducted [29]. However,
Sabunciya et al. did not ﬁnd diﬀerences in immunoreactivity
between PC patients and controls by ELISA using XMRV
env or gag antigen to capture anti-XMRV antibodies [30].
A similar neutralizing antibody assay developed by Groom
et al. could not detect speciﬁc anti-XMRV antibody in
170 CFS patients [31]. These results highlight the con-
troversy in detecting anti-XMRV antibodies due to the
lack of validated assays and well-characterized reference
materials.
Onlamoon et al. infected rhesus macaques with XMRV
to develop an animal model of XMRV infection and
to investigate the viremia and immune response against
XMRV [32]. They found that viremia was detected 4 days
postinfection (PI) with a peak on day 7 for one animal and a
delayed and lower acute viral replication kinetic at days 14–
20 in another animal [32]. The antibody responses to XMRV
were observed during the second week of infection and
boosted upon reexposure, but titers decreased rapidly [32,
33], indicating a weak immune response. The predominant
responses were to the envelope protein gp70 and p15E, and
capsid protein p30 with higher titers to gp70 and p15E than
to p30, especially in acute infection of XMRV. Antibodies
to gp70, p15E, and p30 persisted to 158 days and were
substantiallyboostedbyreinfection,indicatingthattheymay
be useful serologic markers for XMRV infection [33]. Based
on these ﬁndings, direct chemiluminescent immunoassays
(CMIAs) on the automated ARCHITECT instrument system
were developed by using recombinant proteins (p15E, gp70,
and p30) for both capture and detection. The prototype
assays showed 100% sensitivity by detecting all Western Blot
positive serial bleeds from the XMRV-infected macaques
and >99% speciﬁcity with blood donors [33]. This is the
ﬁrst study to investigate the nature and kinetics of the
antibody response to XMRV infection in animal model, and
the ﬁrst immunoassay that has been evaluated by the well-
characterized XMRV-positive animal bleeds.
The US National Cancer Institute (NCI) has invested
considerable eﬀort in developing serological assays for
detection of XMRV infection. They used the Meso Scale
Discovery (MSD) platform and found that reactivity to
XMRVrecombinantproteinsisstatisticallyhigherinXMRV-
positive clinical samples from CFS patients than in normal
donor plasma [34]. Conventional ELISA has been developed
by using recombinant XMRV-proteins to capture antibodies
in samples [30, 35]. In addition, several groups reported the
use of the WB assay for detection of anti-XMRV antibodies
[36, 37].
Unfortunately, all of these assays have not yet been fully
validatedduetolackofreferencereagentsforstandardization
of assays; therefore, it is diﬃcult to make comparisons
of results obtained in diﬀerent laboratories using various-
methodologies. Several groups were unable to detect XMRV-
speciﬁc antibodies in PC and CFS patients as well as healthy
control sera [30, 35, 36, 38]. In some studies, the weak4 Advances in Virology
antibody activity could not be conﬁrmed by other assays,
such as immunoﬂuorescence assay (IFA) or was found to
be nonspeciﬁc cross-reactivity [38]. Groom et al. found that
only one of the 26 samples with neutralizing activity came
from a CFS patient, while 14% (22/157) blood donors were
positive by their neutralizing assay [31]. However, most of
the serological positive samples were also able to neutralize
MLV particles pseudotyped with enveloped proteins from
other viruses, including vesicular stomatitis virus, indicating
signiﬁcant cross-reactivity in serological responses. These
results highlight the danger of overestimating XMRV fre-
quency based on serological assays.
2.3. Other Test Methods. Both FISH and IHC were employed
to localize XMRV within human prostatic tissues, and to
measure the frequency of the infected cells. Urisman et al.
reported that about 0.1∼1.2% of the cells were positive
and most FISH-positive cells were stromal ﬁbroblasts [1].
They also used IHC to stain PC tissues with a monoclonal
antibody against SFFV that was reactive against gag proteins
from a wide range of diﬀerent ecotropic, polytropic, and
xenotropic MuLV strains. However, they observed that only
stromal but not epithelial cells were infected with XMRV
[1]. In contrast, Schlaberg et al. stained prostate tissues
with anti-XMRV sera and found viral protein expression in
23% (54/233) of cases with PC and in 4% (4/101) controls.
XMRV-speciﬁc staining was predominantly observed in
malignant prostatic epithelial cells [23]. However, only 6
out of 54 IHC-positive PC cases were XMRV DNA positive
while none of the controls was positive for the two assays.
Diﬀerences between the two methods were argued to be
attributed to very low viral loads, sampling diﬀerences, and
varying proportions of XMRV-infected cells [23]. Aloia et al.
reported no staining of 596 prostatic adenocarcinomas and
452benignprostatetissuespecimensbyIHCusinganti-MLV
antibodies which reproducibly reacted with XMRV proteins
and stained XMRV-containing cells [39]. They were unable
to stain positive samples from the Schlaberg study, raising
the question of whether the ﬁndings by Schlaberg et al.
were valid [39]. Barnes et al. used T-cell ELISPOT assay
to test responses of PBMCs to XMRV gag peptides as
an evidence of XMRV infection of PBMCs [40]. For ex
vivo T-cell ELISPOT assays, microtiter plates coated with
anti-interferon-γ immunoglobulin G were used to incubate
with XMRV peptides and PBMCs from patients, followed
by incubation with biotinylated interferon-γ antibody and
streptavidin-labeled chromogen. The number of reactive
cells was counted. They found no positive responses to
XMRV gag in the 63 patients infected with HIV-1 or HCV.
However,patientcellswereresponsivetootherantigens,sug-
gesting that the absence of XMRV gag-speciﬁc T cells in their
study. Lee described a novel cell line, Detectors of Exogenous
Retroviral Sequence Elements (DERSE) indicator cells, to
rapidly assess XMRV or XMLV replication in less than 3
days [14]. The DERSE cell uses a retroviral vector containing
an inverted, intron-interrupted green ﬂuorescent protein
(GFP) reporter cassette. XMRV infection permitted GFP
expression, which can be easily monitored by microscopy.
3. Conclusion
Currently, there are no commercially available FDA
approved/licensed tests for detection of XMRV or other
MLV-relatedhumanretroviruses.Standardsforthediagnosis
of XMRV or MLV-related retrovirus infection based
on laboratory test methods have not been established.
The relative sensitivity and speciﬁcity of various assay
methodologies and strategies (i.e., NAT, serology, and
culture) have not been determined and standards for assay
performance have not yet been established. The use of
multiple testing methodologies may be required because
of the biology of the viruses, such as transient viremia and
relatively low-immune response observed in the Macaque
model. In order to avoid false-positive detection, mouse
DNA contamination should be carefully examined and
excluded.
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